Summary
- The U.S. FDA has approved FluMist for self- or caregiver-administration for the prevention of influenza in individuals aged 2 through 49 years.
- FluMist is a nasal spray vaccine approved for use in individuals 2 through 5 years old since 2007, adding to the original approval for ages 5 through 49 in 2003.
- The flu is a contagious respiratory disease that can cause mild to severe illness, particularly in high-risk groups like the elderly and young children.
- FluMist contains weakened live influenza virus strains and may be administered by a healthcare provider or self-administered by individuals or caregivers 18 years of age or older.
- The FDA granted approval to MedImmune LLC for FluMist, and it will be made available through a third-party online pharmacy for self- or caregiver-administration.
The U.S. Food and Drug Administration has recently approved FluMist for self- or caregiver-administration, allowing individuals aged 2 through 49 years to prevent influenza disease caused by influenza virus subtypes A and B. This nasal spray vaccine has been used safely and effectively for many years and is the first influenza vaccine that does not require administration by a healthcare provider. The approval provides a convenient and accessible option for families and individuals to receive their seasonal flu vaccine.
Influenza, commonly known as the flu, is a contagious respiratory disease that can cause various symptoms such as body aches, fever, coughing, sore throat, and fatigue. It can lead to serious complications and even death, especially in high-risk groups like the elderly and young children. With the availability of FluMist for self- or caregiver-administration, individuals can now easily access the vaccine through a third-party online pharmacy. The FDA’s approval of this option reinforces the importance of annual flu vaccination to prevent the spread of the virus and protect public health.
Infectious Diseases, Pediatrics, Public Health & Prevention